CompletedNCT00735371

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Medication studyAges 13–17United States

The study in practice

Understand this study

Listed age limits: 13 years to 17 years.

Listed locations: Little Rock, United States · El Centro, United States and 41 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: October 8, 2008

Recruitment status: Completed
Enrollment listed in the registry: 314
Sponsor: Shire
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 13 Years to 17 Years
Official registry ID: NCT00735371
Official title: Show the full official title
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed

Little Rock · El Centro · Rolling Hills Estates

40 more locations

FAQ

Who is behind this study?

The study sponsor is Shire.

Did this study involve medication?

Yes. The study involved medication, including LDX 30 mg, LDX 50 mg, LDX 70 mg and Placebo.

Who was this study for?

Listed age limits: 13 years to 17 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.